KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Treasury Shares (2016 - 2025)

Jazz Pharmaceuticals has reported Treasury Shares over the past 14 years, most recently at $4.4 million for Q4 2025.

  • Quarterly Treasury Shares rose 464.15% to $4.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.4 million through Dec 2025, up 464.15% year-over-year, with the annual reading at $4.4 million for FY2025, 464.15% up from the prior year.
  • Treasury Shares was $4.4 million for Q4 2025 at Jazz Pharmaceuticals, up from $781000.0 in the prior quarter.
  • Over five years, Treasury Shares peaked at $4.4 million in Q4 2025 and troughed at $781000.0 in Q4 2024.
  • The 5-year median for Treasury Shares is $1.5 million (2024), against an average of $2.2 million.
  • Biggest five-year swings in Treasury Shares: plummeted 78.08% in 2024 and later surged 464.15% in 2025.
  • Tracing JAZZ's Treasury Shares over 5 years: stood at $2.6 million in 2021, then grew by 21.97% to $3.2 million in 2022, then grew by 11.03% to $3.6 million in 2023, then plummeted by 78.08% to $781000.0 in 2024, then surged by 464.15% to $4.4 million in 2025.
  • According to Business Quant data, Treasury Shares over the past three periods came in at $4.4 million, $781000.0, and $1.4 million for Q4 2025, Q4 2024, and Q3 2024 respectively.